Raj Chovatiya, MD, PhD

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

In this segment of his interview, Chovatiya speaks about how new consensus definitions on atopic dermatitis disease activity could impact clinical trials.

In this interview, Chovatiya highlights several key takeaways regarding the latest definitions highlighted by the International Eczema Council.

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

An interview conducted at Maui Derm 2026 highlights a presentation by Raj Chovatiya, MD, PhD, on managing atopic dermatitis and itch in 2026.

Ahead of ACAAI 2025, HCPLive spoke with Chovatiya on challenges in translating these promising immunologic targets into real-world clinical practice.

At ACAAI 2025, HCPLive spoke with Chovatiya on the OX40/OX40L pathway and what makes it an attractive therapeutic target over other established pathways.

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

In this EADV interview, Chovatiya highlights some of his session’s most notable takeaways regarding current treatments and new data in the atopic dermatitis space.

Discover how roflumilast foam transforms treatment for seborrheic dermatitis, showing effectiveness across diverse skin tones.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

These interviews with Chovatiya and Stein Gold highlight a variety of key points from the dermatology-centric EADV Congress 2025 meeting in Paris, France.

In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

Full video: Experts discuss the overlap between immune-mediated inflammatory diseases in GI and dermatology, emphasizing the importance of cross-specialty care.

In the final segment of this HCPLive Special Report, experts discuss lingering unmet needs in cross-specialty care and look ahead to potential areas for improvement.

In part 2 of their HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, continue their in-depth conversation.

In this HCPLive Special Report series, Raj Chovatiya, MD, PhD, and Adelina Hung, MD, discuss the connection between GI and dermatologic care.

Leading experts discuss managing atopic dermatitis in skin of color in a live recording from the 2025 Revolutionizing Atopic Dermatitis Conference.

This interview at RAD 2025 highlights several notes on dose flexibility in atopic dermatitis, with commentary by presenter Raj Chovatiya, MD, PhD.

An expert discusses how new treatments for chronic hand eczema (CHE) are emerging, particularly topical delgocitinib cream, a pan-Janus kinase (JAK) inhibitor that shows promise for treating multiple etiologies of the condition without the limitations of traditional topical steroids.

In this interview, Mona Shahriari, MD, and Raj Chovatiya, MD, PhD, touched on the evolving role of pharmacists and internal medicine doctors in atopic dermatitis.

An expert discusses how chronic hand eczema (CHE) treatment follows a stepwise approach from general care and barrier protection to topical therapies (corticosteroids and calcineurin inhibitors) and systemic options (alitretinoin, immunosuppressives, and newer biologics for atopic dermatitis).

An expert discusses how chronic hand eczema (CHE) significantly impacts patients' daily activities and work productivity, as painful symptoms and limitations make routine tasks challenging, while avoidance recommendations are often difficult to implement.

An expert discusses how chronic hand eczema (CHE) diagnosis relies on clinical features such as erythema, scaling, vesicles, hyperkeratosis, fissures, and erosions, which must be distinguished from atopic dermatitis through a comprehensive patient history and full-body examination.

An expert discusses how risk factors for chronic hand eczema (CHE) include atopic dermatitis, filaggrin mutations, contact allergies, environmental conditions, and occupational exposures, with hand eczema being the most common occupational skin disease.

In this interview, Raj Chovatiya, MD, PhD, describes roflumilast cream's success in addressing unmet needs for atopic dermatitis.